These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22974122)

  • 1. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.
    Silva MM; Thelwell C; Williams SC; Longstaff C
    J Thromb Haemost; 2012 Nov; 10(11):2354-60. PubMed ID: 22974122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
    Bakker AH; Nieuwenbroek NM; Verheijen JH
    Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin.
    de Vries C; Veerman H; Koornneef E; Pannekoek H
    J Biol Chem; 1990 Aug; 265(23):13547-52. PubMed ID: 2143185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prion protein stimulates tissue-type plasminogen activator-mediated plasmin generation via a lysine-binding site on kringle 2.
    Epple G; Schleuning WD; Kettelgerdes G; Kottgen E; Gessner R; Praus M
    J Thromb Haemost; 2004 Jun; 2(6):962-8. PubMed ID: 15140132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis.
    Horrevoets AJ; Smilde A; de Vries C; Pannekoek H
    J Biol Chem; 1994 Apr; 269(17):12639-44. PubMed ID: 8175674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
    Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
    J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA).
    Rijken DC; Barrett-Bergshoeff MM; Jie AF; Criscuoli M; Sakharov DV
    Thromb Haemost; 2004 Jan; 91(1):52-60. PubMed ID: 14691568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN; Meijers JC
    J Thromb Haemost; 2003 Jul; 1(7):1566-74. PubMed ID: 12871292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
    Urano S; Metzger AR; Castellino FJ
    Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets.
    Ni R; Neves MAD; Wu C; Cerroni SE; Flick MJ; Ni H; Weitz JI; Gross PL; Kim PY
    J Thromb Haemost; 2020 Sep; 18(9):2364-2376. PubMed ID: 32506822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
    Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
    J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin.
    Kovács A; Szabó L; Longstaff C; Tenekedjiev K; Machovich R; Kolev K
    Thromb Res; 2014 Jan; 133(1):80-7. PubMed ID: 24094605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.
    Wilhelm OG; Jaskunas SR; Vlahos CJ; Bang NU
    J Biol Chem; 1990 Aug; 265(24):14606-11. PubMed ID: 2117612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis.
    Ho-Tin-Noé B; Rojas G; Vranckx R; Lijnen HR; Anglés-Cano E
    FEBS J; 2005 Jul; 272(13):3387-400. PubMed ID: 15978044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.